

Hybrigenics invests in its genomic capabilities

Helixio, Hybrigenics' genomic division, purchases an Illumina® NextSeq500® next generation sequencer

Paris, 01 October 2014 – Hybrigenics (ALHYG), a bio-pharmaceutical company listed on the Alternext market of Euronext Paris, with a focus on research and development of new treatments of proliferative diseases and specialised in proteomic and genomic scientific services, today announces the acquisition of an Illumina® NextSeq500® sequencer by Helixio, its division in charge of genomic studies and services.

This latest machine from Illumina®, the world leader in next generation sequencing technologies, can sequence the human whole genome or of most plant or animal individual organisms in less than two days. In addition to speed, the flexibility to adapt to the parallel sequencing of the desired number of exomes or transcriptomes with the optimal level of accuracy, is the other important feature of this new equipment.

Helixio, Hybrigenics' genomic division, will take advantage of these properties to deliver customized state-of-the-art sequencing results to its fee-for-service customers from all life sciences. Helixio will also be able to support Hybrigenics' internal R&D studies with newly available genomic information.

"The acquisition of an Illumina® NextSeq500® is an important step forward for Helixio, our genomic division, to tailor its service offering to meet the growing needs of researchers from all life sciences in terms of next generation sequencing," said Remi Delansorne, Hybrigenics' CEO.

About Helixio®

Helixio (www.helixio.com), Hybrigenics' genomic division, offers a wide range of genomic and bioinformatic services in the fields of human, animal or plant biology and diseases. Helixio uses the latest state-of-the-art technologies to study the up- or down-regulation of gene expression, to detect and identify genetic variations from single nucleotide polymorphism (SNP) to whole chromosomal aberrations, and to sequence whole genomes, exomes or transcriptomes. Helixio provides its scientific expertise to design, customize, perform and analyse the genomic experiments best suited to its customers' project needs.

About Hybrigenics

Hybrigenics (www.hybrigenics.com) is a bio-pharmaceutical group listed (ALHYG) on the Alternext market of Euronext in Paris, focusing its internal R&D programs on innovative targets and therapies for the treatment of proliferative diseases and providing cutting-edge proteomic and genomic scientific services.

Hybrigenics' development program is based on inecalcitol, a vitamin D receptor agonist active by oral administration. Inecalcitol has received orphan drug status for chronic lymphocytic leukemia both in Europe and the United States.

Hybrigenics has a research collaboration with Servier on deubiquitinating enzymes and their inhibitors in oncology, neurology, psychiatry, rheumatology, ophthalmology, diabetes and cardiovascular diseases.

Hybrigenics Services (www.hybrigenics-services.com) is the market leader in Yeast Two-Hybrid (Y2H) and related services to identify, validate and inhibit protein interactions for researchers in all areas of life sciences, using its ISO 9001-certified high-throughput Y2H screening platform.

Hybrigenics Corp., based in Cambridge, Mass., is the American subsidiary of Hybrigenics.

HYBRIGENICS

Press Release

HYBRIGENICS is listed on the Alternext market of Euronext Paris

ISIN: FR0004153930

Ticker: ALHYG



Hybrigenics

Rémi Delansorne

CEO

Tel.: +33 (0)1 58 10 38 00

investors@hybrigenics.com

NewCap

Financial communication

Julien Perez / Pierre Laurent

Tel.: +33 (0)1 44 71 94 94

hybrigenics@newcap.fr